Surufatinib
- Generic Name
- Surufatinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H28N6O3S
- CAS Number
- 1308672-74-3
- Unique Ingredient Identifier
- B2K5L1L8S9
- Background
Surufatinib is under investigation in clinical trial NCT02588170 (Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors).
- Indication
单药用于治疗无法手术切除的局部晚期或转移性、进展期非功能性、分化良好（G1、G2）的胰腺和非胰腺来源的神经内分泌瘤（pNETs）。
- Associated Conditions
- -
- Associated Therapies
- -
Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors
- First Posted Date
- 2014-10-20
- Last Posted Date
- 2018-11-13
- Lead Sponsor
- Hutchison Medipharma Limited
- Target Recruit Count
- 81
- Registration Number
- NCT02267967
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
🇨🇳West China Hospital, Sichuan University, Chengdu, Sichuan, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China
Phase I Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors
- First Posted Date
- 2014-05-07
- Last Posted Date
- 2020-07-08
- Lead Sponsor
- Hutchison Medipharma Limited
- Target Recruit Count
- 71
- Registration Number
- NCT02133157
- Locations
- 🇨🇳
Academy of Military Medical Affiliated Hopital, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath